Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation

被引：15
|
作者：
Ma, Y-R [1 ]
Xu, L-P [1 ]
Zhang, X-H [1 ]
Yan, C-H [1 ]
Wang, Y. [1 ]
Wang, F-R [1 ]
Wang, J-Z [1 ]
Chen, Y. [1 ]
Han, W. [1 ]
Chen, Y-H [1 ]
Chen, H. [1 ]
Liu, K-Y [1 ]
Huang, X-J [1 ,2 ]
机构：
[1] Peking Univ, Peoples Hosp, Dept Hematol, Inst Hematol,Beijing Key Lab Hematopoiet Stem Cel, 11 Xizhimen South St, Beijing 100044, Peoples R China
[2] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; VERSUS-HOST-DISEASE; RISK ACUTE-LEUKEMIA; LYMPHOCYTE INFUSION; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; SIBLING TRANSPLANT; ALTERNATIVE DONORS; PROGNOSTIC-FACTORS; MISMATCHED HLA; SINGLE-CENTER;
D O I：
10.1038/bmt.2016.283
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
We investigated the impact of donor type on post-relapse survival (PRS) in 85 patients with hematological relapse after their first allogeneic hematological stem cell transplantation (allo-HSCT) for hematological malignancy. The median follow-up was 64 months among survivors. Both 3-year overall survival and 3-year PRS were similar in haploidentical donor (HID) and matched sibling donor (MRD) transplantation (13.0% +/- 4.7% vs 19.4% +/- 7.1%, P = 0.913 and 7.7 +/- 3.9% vs 9.7 +/- 5.3%, P = 0.667). Higher rates of post-relapse grade II-IV and III-IV acute GvHD (aGvHD) were observed in HID transplantation patients. A higher cumulative incidence of post-relapse extensive chronic GvHD was also observed for HID transplantation patients. Multivariate analyses confirmed that treatment including donor lymphocyte infusion (DLI), late relapse >1 year, and in first CR at transplantation were associated with superior PRS (P = 0.012, hazard ratio (HR) = 0.527 (0.320 - 0.866)); P = 0.033, HR = 0.534 (0.300 - 0.952) and P = 0.046, HR = 0.630 (0.400 - 0.992). The data suggest that post-relapse outcomes are comparable in HID and MRD transplantation, and that DLI is safe for relapsed patients after haploidentical transplantation.
引用
收藏
页码：409 / 414
页数：6
相关论文
共 50 条
  • [1] Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation
    Y-R Ma
    L-P Xu
    X-H Zhang
    C-H Yan
    Y Wang
    F-R Wang
    J-Z Wang
    Y Chen
    W Han
    Y-H Chen
    H Chen
    K-Y Liu
    X-J Huang
    [J]. Bone Marrow Transplantation, 2017, 52 : 409 - 414
  • [2] Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation
    M Solh
    X Zhang
    K Connor
    S Brown
    S R Solomon
    L E Morris
    H K Holland
    A Bashey
    [J]. Bone Marrow Transplantation, 2016, 51 : 949 - 954
  • [3] Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation
    Solh, M.
    Zhang, X.
    Connor, K.
    Brown, S.
    Solomon, S. R.
    Morris, L. E.
    Holland, H. K.
    Bashey, A.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 949 - 954
  • [4] Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
    Hong, Sanghee
    Rybicki, Lisa
    Mclellan, Linda
    Dabney, Jane
    Gerds, Aaron T.
    Rotz, Seth J.
    Kalaycio, Matt
    Hanna, Rabi
    Hamilton, Betty K.
    Majhail, Navneet S.
    Sobecks, Ronald M.
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04): : 217.e1 - 217.e6
  • [5] Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia
    Shin, Jee Yon
    Park, Sung-Soo
    Min, Gi June
    Park, Silvia
    Lee, Sung-Eun
    Yoon, Jae-Ho
    Shin, Seung-Hwan
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Kim, Hee-Je
    Cho, Seok-Goo
    Lee, Jong-Wook
    [J]. BLOOD, 2019, 134
  • [6] Comparable outcomes of haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and unrelated donor transplantation
    Hong, K. T.
    Kang, H. J.
    Choi, J. Y.
    Hong, C. R.
    Park, K. D.
    Shin, H. Y.
    [J]. BONE MARROW TRANSPLANTATION, 2017, 52 : S484 - S484
  • [7] Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant
    Adhikari, Janak
    Gyawali, Bishal
    Sharma, Priyadarshani
    Bhatt, Vijaya Raj
    [J]. FUTURE ONCOLOGY, 2017, 13 (10) : 935 - 944
  • [8] Lower Use of DLI Post Relapse of Malignancy May Result in Shorter Post-Relapse Survival (PRS) in Patients Undergoing T Cell Replete Haploidentical Donor Transplantation (HIDT) Versus Matched Related (MRD) or Matched Unrelated Donor (MUD) Hematopoietic Cell Transplantation (HCT)
    Solh, Melhem
    Zhang, Xu
    Brown, Stacey
    Morris, Lawrence E.
    Holland, H. Kent
    Solomon, Scott R.
    Bashey, Asad
    [J]. BLOOD, 2015, 126 (23)
  • [9] Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse
    Solh, Melhem
    Bashey, Asad
    Solomon, Scott R.
    Morris, Lawrence E.
    Zhang, Xu
    Holland, H. Kent
    [J]. BLOOD, 2021, 138
  • [10] Haploidentical and matched unrelated donor allogeneic hematopoietic stem cell transplantation offer similar survival outcomes for acute leukemia
    Wang, Yin-Che
    Lai, Cheng-Lun
    Chen, Tsung-Chih
    Gau, Jyh-Pyng
    Teng, Chieh-Lin Jerry
    [J]. CANCER REPORTS, 2024, 7 (04)
12345